Vasculitis
From the Journals
Rituximab Not Inferior to Cyclophosphamide in Pediatric Vasculitis
Those who received rituximab required a significantly lower steroid dose than those who received cyclophosphamide or a combination therapy.
From the Journals
Infliximab vs Adalimumab: Which Is Best for Behçet Syndrome?
Both infliximab and adalimumab were found to be effective in achieving remission and enhancing quality of life while having a high level of...
From the Journals
No Benefit to High-Dose IV Vs Oral Steroids in Giant Cell Arteritis
Intravenous methylprednisolone is not significantly beneficial vs oral glucocorticoids in improving visual acuity or survival in patients with...
From the Journals
Frailty, Not Just Advanced Age, Affects ANCA Vasculitis Outcomes
Frailty emerged as an independent risk factor for severe infection and end-stage renal disease or death across different age groups in older...
News from the FDA/CDC
Benralizumab Now FDA Approved to Treat EGPA Vasculitis
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
From the Journals
ANCA-Associated Vasculitis Has Five Unique Patient Clusters
A data-driven analysis of a large cohort of patients with ANCA-associated vasculitis subclassified the condition into five distinct clusters,...
Latest News
Monitor Asthma Patients on Biologics for Remission, Potential EGPA Symptoms During Steroid Tapering
Biologics have revolutionized the treatment of severe asthma, significantly improving patient outcomes.
From the Journals
Risk for Giant Cell Arteritis Rises With Air Pollution Levels
Exposure to high levels of particulate matter with diameter ≤ 10 μm was associated with an increased risk for giant cell arteritis but not...
Feature
New Drugs, Treatment Strategies Aim to Lessen Rheumatic Diseases’ Reliance on Steroids
Selective GC receptor agonists and modulators and GC plus hydroxysteroid dehydrogenase inhibitor combination therapy are some of the approaches...
Conference Coverage
Upadacitinib Proves Successful in First JAK Inhibitor Trial for Giant Cell Arteritis
Results from the SELECT-GCA study showed that upadacitinib (Rinvoq) induced significant and sustained remission in people with new-onset or...
From the Journals
Diagnosing Giant Cell Arteritis Using Ultrasound First Proves Accurate, Avoids Biopsy in Many Cases
In a prospective study, all patients diagnosed with giant cell arteritis using ultrasound maintained their diagnosis for up to 2 years of follow-...